hydroxyindoleacetic acid has been researched along with Nerve Degeneration in 37 studies
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Kainic acid (KA) was employed to induce neuronal lesions in the more dorsal striatum, the caudate-putamen (CP)." | 1.31 | Lesion of caudate-putamen interneurons with kainic acid alters dopamine and serotonin metabolism in the olfactory tubercle of the rat. ( Cubeddu, LX; Guevara, BH; Hoffmann, IS; Torrico, F, 2002) |
| "Nicotine is a neuroteratogen that targets synaptic function during critical developmental stages and recent studies indicate that CNS vulnerability extends into adolescence, the time that smoking typically commences." | 1.31 | Fetal and adolescent nicotine administration: effects on CNS serotonergic systems. ( Ali, SF; Seidler, FJ; Slikker, W; Slotkin, TA; Xu, Z, 2001) |
| "Pretreatment with chlormethiazole (100 mg/kg i." | 1.29 | Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats. ( Green, AR; Hewitt, KE, 1994) |
| "Dexfenfluramine treatment decreased the density of 5-HT uptake sites in the cortex, labelled with [3H]-citalopram, but this partially recovered towards control values at 60 days." | 1.29 | Repeated administration of escalating high doses of dexfenfluramine does not produce morphological evidence for neurotoxicity in the cortex of rats. ( Collins, P; Hindmarsh, JG; Hunt, S; Jenner, P; Rose, S, 1996) |
| " The neurochemical and histological effects of PCA are very similar to those produced by a large dose of methylamphetamine (MA) in that both drugs are toxic to serotonergic nerve terminals and neuronal perikarya in the somatosensory cortex." | 1.27 | Endogenously produced 5,6-dihydroxytryptamine may mediate the neurotoxic effects of para-chloroamphetamine. ( Axt, KJ; Commins, DL; Seiden, LS; Vosmer, G, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (40.54) | 18.7374 |
| 1990's | 16 (43.24) | 18.2507 |
| 2000's | 5 (13.51) | 29.6817 |
| 2010's | 1 (2.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moreira, CG | 1 |
| Barbiero, JK | 1 |
| Ariza, D | 1 |
| Dombrowski, PA | 1 |
| Sabioni, P | 1 |
| Bortolanza, M | 1 |
| Da Cunha, C | 1 |
| Vital, MA | 1 |
| Lima, MM | 1 |
| Ricaurte, GA | 2 |
| Yuan, J | 2 |
| Hatzidimitriou, G | 1 |
| Cord, BJ | 2 |
| McCann, UD | 2 |
| Callahan, BT | 1 |
| Guevara, BH | 1 |
| Torrico, F | 1 |
| Hoffmann, IS | 1 |
| Cubeddu, LX | 1 |
| Götz, ME | 1 |
| Malz, CR | 1 |
| Dirr, A | 1 |
| Blum, D | 1 |
| Gsell, W | 1 |
| Schmidt, S | 1 |
| Burger, R | 1 |
| Pohli, S | 1 |
| Riederer, P | 2 |
| Staley, NA | 1 |
| Poleksy, HF | 1 |
| Bensch, KG | 1 |
| Björklund, A | 2 |
| Wiklund, L | 1 |
| Carruba, MO | 1 |
| Keller, HH | 1 |
| Da Prada, M | 1 |
| Parenti, M | 1 |
| Tirone, F | 1 |
| Olgiati, VR | 1 |
| Groppetti, A | 1 |
| Johnson, H | 1 |
| Ulfhake, B | 1 |
| Dagerlind, A | 1 |
| Bennett, GW | 1 |
| Fone, KC | 1 |
| Hökfelt, T | 1 |
| Hewitt, KE | 1 |
| Green, AR | 6 |
| Hörtnagl, H | 1 |
| Berger, ML | 1 |
| Havelec, L | 1 |
| Hornykiewicz, O | 2 |
| Colado, MI | 5 |
| Rose, S | 1 |
| Hunt, S | 1 |
| Collins, P | 1 |
| Hindmarsh, JG | 1 |
| Jenner, P | 1 |
| Murray, TK | 1 |
| Williams, JL | 1 |
| Misra, A | 1 |
| Dethy, S | 1 |
| Manto, M | 1 |
| Bastianelli, E | 1 |
| Gangji, V | 1 |
| Laute, MA | 1 |
| Goldman, S | 1 |
| Hildebrand, J | 1 |
| Zheng, Y | 1 |
| Laverty, R | 1 |
| Granados, R | 3 |
| O'Shea, E | 3 |
| Esteban, B | 3 |
| Reynolds, GP | 1 |
| Dalton, CF | 1 |
| Tillery, CL | 1 |
| Mangiarini, L | 1 |
| Davies, SW | 1 |
| Bates, GP | 1 |
| Vollenweider, FX | 1 |
| Gamma, A | 1 |
| Liechti, M | 1 |
| Huber, T | 1 |
| Xu, Z | 1 |
| Seidler, FJ | 1 |
| Ali, SF | 1 |
| Slikker, W | 1 |
| Slotkin, TA | 1 |
| Bowen, DM | 1 |
| White, P | 1 |
| Spillane, JA | 1 |
| Goodhardt, MJ | 1 |
| Curzon, G | 1 |
| Iwangoff, P | 1 |
| Meier-Ruge, W | 1 |
| Davison, AN | 1 |
| Klawans, H | 1 |
| Wuttke, W | 1 |
| Baumgarten, HG | 1 |
| Lachenmayer, L | 1 |
| Fenske, M | 1 |
| Klemm, HP | 1 |
| Birkmayer, W | 1 |
| Danielczyk, W | 1 |
| Neumayer, E | 1 |
| Pehek, EA | 1 |
| Crock, R | 1 |
| Yamamoto, BK | 1 |
| Zhou, FC | 1 |
| Azmitia, EC | 1 |
| Orer, HS | 1 |
| Merahi, N | 1 |
| Nosjean, A | 1 |
| Fattaccini, CM | 1 |
| Laguzzi, R | 1 |
| Scatton, B | 1 |
| Dennis, T | 1 |
| L'Heureux, R | 1 |
| Monfort, JC | 1 |
| Duyckaerts, C | 1 |
| Javoy-Agid, F | 1 |
| Ichikawa, N | 1 |
| Commins, DL | 1 |
| Axt, KJ | 1 |
| Vosmer, G | 1 |
| Seiden, LS | 1 |
| Battaglia, G | 1 |
| Yeh, SY | 1 |
| De Souza, EB | 1 |
| Andén, NE | 1 |
| Carlsson, A | 1 |
| Lindqvist, M | 1 |
| Magnusson, T | 1 |
| Atack, C | 1 |
| Sharpe, JA | 1 |
| Rewcastle, NB | 1 |
| Lloyd, KG | 1 |
| Hill, M | 1 |
| Tasker, RR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)[NCT00271596] | Phase 2 | 33 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Full Scale Name: The Executive Composite Score (ECS). Definition: Subscales were averaged to compute this composite total score. The ECS is the weighted average of performance on 6 subtests of executive function, including (1) the Controlled Oral Word Association Test, (2) Symbol Digit Modalities test; (3) Stroop Color Word Test (Interference Trial), (4) Trail Making test (Part B), (5) Letter-Number Sequencing, and (6) Animal Naming. Construct Measured: Thinking tasks involving planning, working memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, and task switching. ECS Scale Range: The ECS score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on executive functioning tasks. Change Calculation Details: Compares change in executive functioning performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.005 |
| Placebo | 0.172 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: Compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.67 |
| Placebo | 1.23 |
Full Scale Name: Letter Number Sequencing (LNS) subtest from the Wechsler Adult Intelligence Scale (WAIS) third edition. Definition: LNS is a task that requires the reordering of an initially unordered set of letters and numbers. Construct Measured: Working memory. LNS Score Range: Raw scores may range from 0 to 21, where lower scores indicate poorer performance in working memory. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.113 |
| Placebo | 0.225 |
Semantic Fluency Score. Definition: The Semantic Fluency Score is the number of words a person can produce given a category, including naming (1) Animal names, (2) Fruit names, (3) Boy names, (4) Girl names, and (5) Vegetable names. Construct Measured: Working memory and verbal initiation. Scale Range: The Semantic Fluency Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on working memory tasks. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) where patients named fruit names to the weighted average of visits 5 (week 12) & 6 (week 15) where patients named girl names and vegetable names respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.386 |
| Placebo | 0.664 |
"Full Scale Name: Stroop Interference subtest from The Stroop Color and Word Test. Definition: Participants are asked to name the ink color in which a word is printed when the word itself (which is irrelevant to the task) is the name of a different color rather than the same color. For example, participants may be asked to say red to the word blue printed in red ink. Constructs Measured: Selective attention, response inhibition, cognitive flexibility, and processing speed. Scale Range: The Stroop Interference score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.256 |
| Placebo | -0.046 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: This analysis was restricted to a subgroup and, accordingly, does not reflect the total number of participants as reported in the Participant Flow. This analysis compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.10 |
| Placebo | 1.50 |
Full Scale Name: The Symbol Digit Modalities Test (SDMT). Definition: The SDMT screens for organic cerebral dysfunction by having the examinee use a reference key to pair specific numbers with given geometric figures in 90 seconds. Construct Measured: Attention, processing speed, and working memory. SDMT Scale Range: Raw scores may range from 0 to 110, where lower scores indicate poorer performance. Change Calculation Details: Compares change in performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.227 |
| Placebo | -0.170 |
Full Scale Name: The Total Functional Capacity (TFC) subscale from the Unified Huntington's Disease Rating Scale (UHDRS). Definition: The TFC is a score that classifies five stages of Huntington's Disease and five levels of function in the domains of workplace, finances, domestic chores, activities of daily living and requirements for unskilled or skilled care. Construct Measured: Activities of Daily Living. Scale Range: The TFC score ranges from 0 to 13, where lower scores indicate poorer performance in activities of daily living. Change Calculation Details: Compares change in TFC performance from Baseline (week -4) to the weighted average of visits 4 (week 6) and 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.54 |
| Placebo | -0.06 |
"Full Scale Name: Trail Making Test Part B (TMT-B). Definition: The TMT-B test requires participants to connect-the-dots of 25 consecutive targets on a sheet of paper where the subject alternates between numbers and letters, going in both numerical and alphabetical order. Constructs Measured: Attention, set shifting, and processing speed. Scale range: The TMT-B score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.087 |
| Placebo | 0.405 |
Full Scale Name: The Verbal Fluency Score (VFC). Definition: The VFC is the number of words a person can produce given a letter, including (1) Naming words that start with F, A, and S; (2) naming words that start with K, W, and R; (3) naming words that start with V, I, and P; (4) naming words that start with O, G, and B; (5) naming words that start with E, N, and T; and (6) naming words that start with J, C, and S. Construct Measured: Verbal initiation and flexibility. Scale Range: The Verbal Fluency Composite Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in verbal initiation and flexibility from visit 2 (week 0) where patients named words starting with O, G, and B to the weighted average of visits 5 (week 12) and 6 (week 15) where patients named words starting with E, N, and T, and J, C, and S respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.140 |
| Placebo | 0.071 |
1 review available for hydroxyindoleacetic acid and Nerve Degeneration
| Article | Year |
|---|---|
Amine precursors in neurologic disorders and the psychoses.
Topics: Acetylcholine; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindo | 1975 |
36 other studies available for hydroxyindoleacetic acid and Nerve Degeneration
| Article | Year |
|---|---|
Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin.
Topics: Animals; Avoidance Learning; Disease Models, Animal; Dopaminergic Neurons; Exploratory Behavior; Hyd | 2012 |
RETRACTED: Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy").
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Axons; Brain; Carrier Proteins; Corpus Str | 2002 |
Effect of glucoprivation on serotonin neurotoxicity induced by substituted amphetamines.
Topics: Amphetamines; Animals; Antimetabolites; Biogenic Monoamines; Body Temperature; Carrier Proteins; Deo | 2002 |
Lesion of caudate-putamen interneurons with kainic acid alters dopamine and serotonin metabolism in the olfactory tubercle of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cell Death; Dopamine; Dose-Response Relat | 2002 |
Brain aging phenomena in migrating sockeye salmon Oncorhynchus nerka nerka.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animal Migration; Animals; Antioxidants; Apoptosis; Brain; Ca | 2005 |
Fine structural and biochemical studies on the malignant ganglioneuroma.
Topics: Adrenal Gland Neoplasms; Child, Preschool; Creatinine; Female; Ganglioneuroma; Humans; Hydroxyindole | 1967 |
Mechanisms of regrowth of the bulbospinal serotonin system following 5,6-dihydroxytryptamine induced axotomy. I. Biochemical correlates.
Topics: 5,6-Dihydroxytryptamine; Animals; Axons; Female; Hydroxyindoleacetic Acid; Medulla Oblongata; Nerve | 1980 |
Long-lasting depletion of spinal cord 5-hydroxytryptamine or catecholamines after intraspinal injection of 5,7-dihydroxytryptamine or 6-hydroxydopamine to newborn rats.
Topics: 5,7-Dihydroxytryptamine; Animals; Animals, Newborn; Brain; Dihydroxytryptamines; Dopamine; Female; H | 1983 |
Presence of opiate receptors on striatal serotoninergic nerve terminals.
Topics: Animals; Corpus Striatum; Dopamine; Enkephalin, Methionine; Fenfluramine; Hydroxyindoleacetic Acid; | 1983 |
The serotoninergic bulbospinal system and brainstem-spinal cord content of serotonin-, TRH-, and substance P-like immunoreactivity in the aged rat with special reference to the spinal cord motor nucleus.
Topics: Aging; Animals; Aromatic-L-Amino-Acid Decarboxylases; Axons; Brain Stem; Fluorescent Antibody Techni | 1993 |
Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats.
Topics: Animals; Chlormethiazole; Dizocilpine Maleate; Haloperidol; Hydroxyindoleacetic Acid; Male; N-Methyl | 1994 |
Role of glucocorticoids in the cholinergic degeneration in rat hippocampus induced by ethylcholine aziridinium (AF64A).
Topics: Acetylcholine; Adrenalectomy; Animals; Aziridines; Cerebral Ventricles; Choline; Choline O-Acetyltra | 1993 |
The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones.
Topics: Analysis of Variance; Animals; Binding, Competitive; Cerebral Cortex; Cyclic N-Oxides; Free Radicals | 1995 |
Repeated administration of escalating high doses of dexfenfluramine does not produce morphological evidence for neurotoxicity in the cortex of rats.
Topics: Animals; Appetite Depressants; Binding Sites; Biomarkers; Cerebral Cortex; Citalopram; Fenfluramine; | 1996 |
The spin trap reagent PBN attenuates degeneration of 5-HT neurones in rat brain induced by p-chloroamphetamine but not fenfluramine.
Topics: Animals; Body Temperature; Brain; Brain Chemistry; Cyclic N-Oxides; Fenfluramine; Hydroxyindoleaceti | 1996 |
Cerebellar spongiform degeneration induced by acute lithium intoxication in the rat.
Topics: Acute Disease; Animals; Cerebellar Diseases; Cerebellum; Dopamine; Homovanillic Acid; Hydroxyindolea | 1997 |
Role of brain nitric oxide in (+/-)3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats.
Topics: Animals; Body Temperature; Enzyme Activation; Enzyme Inhibitors; Hydroxyindoleacetic Acid; Indazoles | 1998 |
Role of hyperthermia in the protective action of clomethiazole against MDMA ('ecstasy')-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR.
Topics: Animals; Body Temperature; Brain Chemistry; Chlormethiazole; Excitatory Amino Acid Antagonists; Feve | 1998 |
The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy').
Topics: Animals; Body Temperature; Brain; Cerebral Cortex; Corpus Striatum; Dose-Response Relationship, Drug | 1998 |
Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation.
Topics: Animals; Brain Chemistry; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; | 1999 |
In vivo evidence against clomethiazole being neuroprotective against MDMA ('ecstasy')-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism.
Topics: Animals; Biotransformation; Body Temperature; Brain; Cerebral Cortex; Chlormethiazole; Corpus Striat | 1999 |
Is a single dose of MDMA harmless?
Topics: Animals; Clinical Trials as Topic; Ethics, Medical; Hallucinogens; Humans; Hydroxyindoleacetic Acid; | 1999 |
Fetal and adolescent nicotine administration: effects on CNS serotonergic systems.
Topics: Aging; Animals; Binding Sites; Brain; Carrier Proteins; Embryo, Mammalian; Female; Hydroxyindoleacet | 2001 |
Accelerated ageing or selective neuronal loss as an important cause of dementia?
Topics: Aged; Aging; Alzheimer Disease; Atrophy; Caudate Nucleus; Cell Count; Choline O-Acetyltransferase; D | 1979 |
De- and regeneration of brain serotonin neurons following 5,7-dihydroxytryptamine treatment: effects on serum LH, FSH and prolactin levels in male rats.
Topics: 5,6-Dihydroxytryptamine; Animals; Follicle Stimulating Hormone; Hydroxyindoleacetic Acid; Hypothalam | 1977 |
Dopaminergic supersensitivity in parkinsonism.
Topics: Aged; Benzyl Compounds; Brain; Brain Chemistry; Dopamine; Drug Therapy, Combination; Female; Humans; | 1975 |
Selective subregional dopamine depletions in the rat caudate-putamen following nigrostriatal lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucleus; Corpus Striatum; Dopamine; Homovanillic Ac | 1992 |
Neurotrophic factor for serotonergic neurons prevents degeneration of grafted raphe neurons in the cerebellum.
Topics: Animals; Cell Count; Cerebellum; Dose-Response Relationship, Drug; Graft Survival; Hippocampus; Hydr | 1990 |
Cardiovascular effects of the local injection of 5,7-dihydroxytryptamine into the nodose ganglia and nucleus tractus solitarius in awake freely moving rats.
Topics: 5,7-Dihydroxytryptamine; Animals; Blood Pressure; Electrodes, Implanted; Electroencephalography; Ele | 1991 |
Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients.
Topics: Aged; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Nerve Degeneratio | 1986 |
Study on monoamine metabolite contents of cerebrospinal fluid in patients with neurodegenerative diseases.
Topics: Adult; Aged; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydr | 1986 |
Endogenously produced 5,6-dihydroxytryptamine may mediate the neurotoxic effects of para-chloroamphetamine.
Topics: 5,6-Dihydroxytryptamine; Amphetamines; Animals; Brain Chemistry; Hippocampus; Hydroxyindoleacetic Ac | 1987 |
MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Biological Transport, Active; Brain; Dose-Resp | 1988 |
Effect of acute axotomy (spinal cord transection) on the turnover of 5-hydroxytryptamine.
Topics: Acetamides; Amphetamine; Animals; Catechols; Fenclonine; Hallucinogens; Hydroxyindoleacetic Acid; Ly | 1974 |
Effect of acute transection on the synthesis and turnover of 5-HT in the rat spinal cord.
Topics: 5-Hydroxytryptophan; Animals; Carboxy-Lyases; Cordotomy; Hydroxyindoleacetic Acid; Male; Nerve Degen | 1973 |
Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation.
Topics: Basal Ganglia; Carboxy-Lyases; Cerebellum; Cerebral Cortex; Corpus Striatum; Diencephalon; Dihydroxy | 1973 |